How this fungus influences the development of melanoma cells has for the first time been explained by the MicrobiomicsEHU group of the University of the Basque Country. The results pave the way for using antifungal therapies to complement conventional treatment to combat the most deadly skin cancer.

A multidisciplinary team of University of Cincinnati Cancer Center researchers has received a $40,000 Ride Cincinnati grant to study the use of a delayed release preparation or wafer of an immunostimulatory molecule known as IL-15 to stimulate the central nervous system immune system after surgery to remove glioblastoma brain tumors.

It is with great pleasure that we announce that the Ludwig Institute for Cancer Research has established the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine’s Sandra and Edward Meyer Cancer Center.

In a prospective imaging study of 200 adults with lung cancer, photon-counting CT reduced radiation exposure, had fewer adverse reactions and provided higher image quality and better detection of malignant features compared with conventional CT.

People with ulcerative proctitis, a milder and more limited form of ulcerative colitis, are not at higher risk of developing rectal cancer than the general population. This is shown in a new Swedish registry study from Karolinska Institutet, published in Gastroenterology. The findings may contribute to more individualized follow-up of patients with inflammatory bowel disease.

A new study by cell biologists at the University of California, Santa Cruz, in Nature Communications suggests that an early first pregnancy may protect against breast cancer decades later by preventing age-related changes in breast cells that are linked to tumor formation. Using a mouse model designed to mimic human aging and reproductive history, researchers found that pregnancy fundamentally alters how mammary tissue ages—reducing the buildup of abnormal cells that have the ability to change their identity in a way that could seed cancer in later life.

Current drugs for pancreatic cancer lose effectiveness within months because the tumour becomes resistant. The group from Spain’s National Cancer Research Centre (CNIO) has been able to avoid the development of resistance in animal models with a combined triple therapy.

 

These results “pave the way for the design of combined therapies that may improve survival,” the authors indicate, although this will not happen in the short term. The results are published in PNAS.

 

Mariano Barbacid, head of the Experimental Oncology Group at CNIO, emphasises that “we are not yet in a position to carry out clinical trials with this triple therapy.”